These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37085653)

  • 1. Prolactin-induced protein (PIP) increases the sensitivity of breast cancer cells to drug-induced apoptosis.
    Urbaniak A; Jablonska K; Suchanski J; Partynska A; Szymczak-Kulus K; Matkowski R; Maciejczyk A; Ugorski M; Dziegiel P
    Sci Rep; 2023 Apr; 13(1):6574. PubMed ID: 37085653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression.
    Suchanski J; Grzegrzolka J; Owczarek T; Pasikowski P; Piotrowska A; Kocbach B; Nowak A; Dziegiel P; Wojnar A; Ugorski M
    Breast Cancer Res; 2018 Nov; 20(1):133. PubMed ID: 30400820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone.
    Yang YP; Kuo HS; Tsai HD; Peng YC; Lin YL
    Breast Cancer Res; 2005; 7(1):R19-27. PubMed ID: 15642166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.
    Naderi A; Meyer M
    Breast Cancer Res; 2012 Jul; 14(4):R111. PubMed ID: 22817771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin Induced Protein (PIP) is a potential biomarker for early stage and malignant breast cancer.
    Gangadharan A; Nyirenda T; Patel K; Jaimes-Delgadillo N; Coletta D; Tanaka T; Walland AC; Jameel Z; Vedantam S; Tang S; Mannion C; Lee GY; Goy A; Pecora A; Suh KS
    Breast; 2018 Jun; 39():101-109. PubMed ID: 29656222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-138-5p improves the chemosensitivity of MDA-MB-231 breast cancer cell line to paclitaxel.
    Rasoolnezhad M; Safaralizadeh R; Hosseinpour Feizi MA; Banan-Khojasteh SM; Roshani Asl E; Lotfinejad P; Baradaran B
    Mol Biol Rep; 2023 Oct; 50(10):8407-8420. PubMed ID: 37620737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin-induced protein as a potential therapy response marker of adjuvant chemotherapy in breast cancer patients.
    Jablonska K; Grzegrzolka J; Podhorska-Okolow M; Stasiolek M; Pula B; Olbromski M; Gomulkiewicz A; Piotrowska A; Rys J; Ambicka A; Ong SH; Zabel M; Dziegiel P
    Am J Cancer Res; 2016; 6(5):878-93. PubMed ID: 27293986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.
    Zoli W; Ulivi P; Tesei A; Fabbri F; Rosetti M; Maltoni R; Giunchi DC; Ricotti L; Brigliadori G; Vannini I; Amadori D
    Breast Cancer Res; 2005; 7(5):R681-9. PubMed ID: 16168113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of RSK4 reverses doxorubicin resistance in human breast cancer cells via PI3K/AKT signalling pathway.
    Mei Y; Liao X; Zhu L; Yang H
    J Biochem; 2020 Jun; 167(6):603-611. PubMed ID: 31960922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity.
    Howell SJ; Anderson E; Hunter T; Farnie G; Clarke RB
    Breast Cancer Res; 2008; 10(4):R68. PubMed ID: 18681966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
    Wu H; Gu J; Zhou D; Cheng W; Wang Y; Wang Q; Wang X
    J Cell Mol Med; 2020 Aug; 24(15):8589-8602. PubMed ID: 32652877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer.
    Li J
    BMC Cancer; 2023 Apr; 23(1):353. PubMed ID: 37069549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.
    Liu H; Wang G; Yang L; Qu J; Yang Z; Zhou X
    PLoS One; 2016; 11(12):e0168406. PubMed ID: 27977766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isorhamnetin induces cell cycle arrest and apoptosis by triggering DNA damage and regulating the AMPK/mTOR/p70S6K signaling pathway in doxorubicin-resistant breast cancer.
    Yang T; Xiao Y; Liu S; Luo F; Tang D; Yu Y; Xie Y
    Phytomedicine; 2023 Jun; 114():154780. PubMed ID: 37004402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner.
    Baniwal SK; Chimge NO; Jordan VC; Tripathy D; Frenkel B
    PLoS One; 2014; 8(6):e62361. PubMed ID: 23755096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
    Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo.
    Chen Q; Liu Y; Zhu XL; Feng F; Yang H; Xu W
    BMC Cancer; 2019 Mar; 19(1):211. PubMed ID: 30849956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
    Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
    Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
    Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
    Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.